The trial was terminated early due to sponsor strategic considerations after enrolling only 23 of the planned participants, completing in November 2022, with results showing the compound was well-tolerated but efficacy data limited due to early termination and small sample size
August 2025: Viking Therapeutics announced positive topline Phase II VENTURE-Oral results for VK2735 tablet, a once-daily oral dual GLP-1/GIP receptor agonist, with up to 12.2% mean weight loss after 13 weeks
Lipids in health and disease , 11 , 165
Understanding these differences, such as Ozempic versus Mounjaro, can guide your treatment choice
Thanks to its blend of amino acids (Citrulline, Beta-Alanine, Agmatine Sulfate) and essential electrolytes, it helps support muscle recovery and maintain the bodys mineral balance